Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients with Metastatic Malignant Melanoma Treated with Targeted Therapies or Immunotherapy ( MALT )

Inclusion Criteria

• •Patients in metastatic situation for a malignant melanoma inoperable stage IIIB or IIIC or stage IV
• •In first line of treatment by a targeted therapy (only or in association) or immunotherapy
• •Every histological types of cutaneous or mucous malignant melanoma (excepted choroid melanomas)
• •The tumor must be mutates for BRAF or NRAS
• •The mutation status must have been realized in the Laboratory Pathology Clinical and Experimental (LPCE) of the CHU de Nice analysis of the status on-site metastatic mutational and/or primitive tumor must
• •Membership or beneficiary of the national insurance scheme